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In specialized movement disorder centers, Parkinson’s disease (PD) is wrongly diagnosed in 6 to 25% of cases. To
improve the accuracy of the clinical diagnosis, it is necessary to have a reliable and practical reference standard.
Dopamine transporter single-photon emission computed tomography (DAT SPECT) imaging might have the
potential (high diagnostic accuracy and practical to use) to act as reference standard in detecting nigrostriatal cell
loss in patients with (early stage) parkinsonism. We performed a systematic review to evaluate if DAT SPECT imaging
can be used as such. Relevant studies were searched in the MEDLINE and EMBASE databases. Studies were selected
when they met the following criteria: (1) all patients were adults with a clinical diagnosis of PD or clinically uncertain
parkinsonism and (2) the study reported original data. In addition, studies needed to fulfill one of the two
following criteria: (1) patients underwent at least one DAT SPECT and had a neuropathological confirmed
diagnosis and (2) patients underwent at least two DAT SPECT scans, performed at least 2 years apart. The search
identified 1,649 articles. Eight studies fulfilled our selection criteria and were included in this review. There was
only one study including patients with diagnostic uncertainty. Sensitivity and specificity of DAT SPECT imaging
to detect nigrostriatal cell loss were 98%. The other studies included patients with a diagnosis of PD in whom
there was no uncertainty. In these studies, sensitivity was 100%. Our systematic review indicates that DAT SPECT
imaging seems to be accurate to detect nigrostriatal cell loss in patients with parkinsonism.
Keywords: Diagnostic accuracy; Clinical diagnosis; Parkinson’s disease; Parkinsonism; Dopamine transporter;
Single-photon emission computed tomography; Nigrostriatal cell lossReview
Introduction
Parkinsonism is a clinical syndrome characterized by
bradykinesia and at least one of the following symptoms:
rest tremor, muscular rigidity, and postural instability.
Parkinsonism is most commonly caused by idiopathic
Parkinson’s disease (PD) [1,2]. However, parkinsonism is
also a prominent feature in, for example, progressive
supranuclear palsy (PSP), multiple system atrophy (MSA),
psychogenic parkinsonism, dementia with Lewy bodies* Correspondence: s.r.suwijn@amc.uva.nl
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in any medium, provided the original work is p(DLB), vascular parkinsonism, and drug-induced parkin-
sonism. There is no definite test to confirm the cause of
parkinsonism in clinical practice, except for the vascular
causes of parkinsonism. Therefore, diagnostic criteria have
been developed in the past 20 years [3-6]. Although the
diagnosis is straightforward when patients have a classic
presentation, establishing the cause of parkinsonism can
be challenging, especially in early stages [7,8]. In special-
ized movement disorder centers, PD is wrongly diagnosed
in 6 to 25% of cases [4,9-11]. General neurologists may
even make a misdiagnosis up to 35% [7]. In a community-
based study in Wales, only 53% of patients, treated with
antiparkinson medication in primary care, met the Queen
Square Brain Bank criteria for the clinical diagnosis of PDn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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specialist [12].
The different causes of parkinsonism can be classified
into two distinct groups; diseases with nigrostriatal cell
loss (e.g., PD, MSA, PSP, and DLB) and diseases without
nigrostriatal cell loss (e.g., psychogenic parkinsonism,
dystonic tremor, dopa-responsive dystonia, and drug-
induced parkinsonism). This classification is of clinical
importance since the prognosis is considerably worse in
parkinsonism characterized by loss of nigrostriatal cells
[13]. Patients without nigrostriatal cell loss, except for
dopa-responsive dystonia, do not benefit from treatment
with dopaminomimetics and require different treatment
[5,13,14].
The current reference standard (or gold standard) of
parkinsonism is pathological evaluation. Although accur-
ate, it is not a practical standard for the validation of
new diagnostic tools because the time between diagnosis
and death is often decades. Therefore, there is a need for
an alternative in vivo reference standard to detect
nigrostriatal dopaminergic cell loss in patients with
parkinsonism.
Several different diagnostic tools have been evaluated
in their ability to detect nigrostriatal cell loss. The most
widely used tests are dopamine transporter single-
photon emission computed tomography (DAT SPECT),
[18 F]DOPA positron emission tomography (PET), and
transcranial sonography (TCS).
Tests used in establishing the cause of Parkinsonism
PET is a radiotracer-based method that can assess the
in vivo function of the dopaminergic and other neuro-
transmitter systems. [18 F]DOPA PET is a reliable tool to
establish nigrostriatal cell loss but not very practical in
clinical practice because the technique is only available
in a limited number of centers, is expensive, and expert-
ise in cerebral PET imaging is essential [15,16].
DAT SPECT imaging - a practical, less expensive, and
more widely available technique than [18 F]DOPA PET -
has been incorporated in most centers as diagnostic tool
[17,18]. DAT tracers like [123I]FP-CIT are typically used.
Recent studies have shown that DAT SPECT imaging
might be a sensitive method to establish nigrostriatal
dopaminergic degeneration [19-24]. For example, people
with subclinical and even preclinical PD already have
clear deficits of the nigrostriatal pathway [21,25-28].
Also, if the scan does not show a nigrostriatal deficit, it
is highly unlikely that the patient suffers from symptoms
caused by nigrostriatal cell loss [11,29,30]. SPECT with
tracers labeling postsynaptic dopamine D2/3 receptors
(e.g., [123I]Iodobenzamide or [123I]Iodobenzofuran) shows
a relatively low diagnostic accuracy, 59 to 80% sensitivity
and 46 to 50% specificity in differentiating PD from non-
neurodegenerative diseases [31].Hyperechogenicity in the area of the midbrain has
been consistently found in 79 to 90% of patients with
PD using TCS [27,32-36]. However, in 6 to 12% of
healthy volunteers, hyperechogenicity of the substantia
nigra is also found [33,36,37]. This is even higher (16%)
in patients with essential tremor [38].
To summarize, DAT SPECT imaging appears to be the
most suitable candidate to act as reference standard in
detecting nigrostriatal cell loss in patients with (early
stage) parkinsonism. Therefore, we performed a system-




We searched the electronic databases MEDLINE and
EMBASE using the entire time scale up to July 2013.
Both search strategies are included in Additional file 1.
Furthermore, we searched the reference lists of all rele-
vant articles to identify additional published studies for
possible inclusion in the review. We did not impose any
language restrictions.
Selection of studies
The list of titles and abstracts was screened by two inde-
pendent reviewers (SRS and CVB) for eligible studies.
Studies were selected according to the following inclu-
sion criteria: (1) all patients were adults with a clinical
diagnosis of PD or clinically uncertain parkinsonism and
(2) the study reported original data. In addition, studies
needed to fulfill one of the two following criteria: (1)
patients underwent at least one DAT SPECT during
their life and had postmortem neuropathological evalu-
ation or (2) patients underwent at least two DAT SPECT
scans, performed at least 2 years apart. We anticipated
that there were only a few studies with DAT SPECT im-
aging and neuropathological evaluation as reference test
(gold standard) available. Therefore, we also included
studies that used a second DAT SPECT scan.
The interval of 2 years was chosen to make sure the
second DAT SPECT scan would detect any nigrostriatal
cell loss. With an annual decline of 5.5 to 7.1% of dopa-
minergic neurons in PD and even more in atypical par-
kinsonian syndromes, a scan at least 2 years later would
show a marked decline if nigrostriatal cell loss was
present but not visible on the baseline scan [23,39].
All study designs were included with the exception of
case reports, case series (less than five patients), and
case-control studies. We did not impose restrictions
regarding the type of radiotracer used (e.g., [123I]FP-CIT
or [123I]β-CIT). If investigators published several reports
based on data from a single study population, we se-
lected the most complete report. Articles were excluded
if information on diagnostic accuracy (e.g., sensitivity
Suwijn et al. EJNMMI Research  (2015) 5:12 Page 3 of 8and specificity) could not be derived from the data and
could not be obtained from the authors. In all cases,
disagreements about study selection were resolved by
consensus and a third reviewer (JB) was consulted if dis-
agreement persisted.
Data extraction and risk of bias
Data were extracted by the two reviewers (SRS and
CVB) independently using an extraction form designed
for this review. We extracted data on the diagnostic
accuracy of the studies, the baseline characteristics of
studied patients (e.g., disease duration, age at imaging,
Hoehn and Yahr score, and Unified Parkinson’s Disease
Rating Scale score). We also extracted data on the
SPECT technique, which radiotracer was used, handling
of DAT interfering medication, patient preparation, test
interpretation, technical failures, and assessors (e.g.,
knowledge of other test results). Results were compared,
and discrepancies between the two reviewers were re-
solved in a meeting.
The Quality Assessment of Diagnostic Accuracy Studies
2 (QUADAS 2) checklist was used to assess the methodo-
logical quality of the included studies. The QUADAS 2
tool is structured in a series of questions which should be8 studies included in analysis





6 studies with 2 or
more DAT SPECT
scans
1649 records after removal of
duplicates
2239 records identified through
database searching
0 record
Figure 1 Flowchart of eligible studies.answered ‘yes’, ‘no’, or ‘unclear’ and aims to evaluate the
risk of different types of bias [40].
Statistical analysis and data synthesis
For each study, patient and study characteristics were
summarized using descriptive statistics. Diagnostic ac-
curacy was described in terms of sensitivity and specifi-
city rates with their 95% confidence intervals (CI). We
did not perform a meta-analysis because we included a
heterogeneous group of patients with a clinical diagnosis
of PD as well as with clinically uncertain parkinsonism
in this review. This alters the spectrum of disease and
non-disease in the population, which may have strong
impact on test accuracy.
Results
Literature search and study selection
Figure 1 shows the results of the Additional file 1 search
and the study selection. We identified 2,239 articles.
After duplicate removal, 1,649 articles remained. A total
of 1,632 articles were excluded because they did not ful-
fill our selection criteria. The large majority of these
studies were excluded because they did not employ mul-
tiple DAT SPECT scans or neuropathological evaluation.9 Full-text articles excluded:
Overlapping study population (n=5)
Missing data (n=4)
dies with DAT SPECT
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3.6¥, 1 to 6* 57.0, 40 to
76*
2.0 ± 0.8 - 2.0 IPT Template Unclear Unclear
Marek,
2001 [22]




2.5¥ ± 2.4 60.0 ± 11.7 1.8 ± 0.7 18.2 ± 8.7 2.3 ± 0.9 Bet Drawn Unclear Yes
Pirker,
2002 [23]














2.4ǂ 60.8 ± 4.8 1.5 ± 0.3 9.6 ± 1.3 3.0 fpc Visual Yes Yes
Isaias,
2010 [48]



























7.9¥ ± 6.3 70.8 ± 4.3 - 35.8 ± 11.9 3.3 ± 1.7ʠ fpc Template Unclear Unclear
Eggers,
2012 [45]




3.9¥ 61.7 ± 11.2 - 25.9 ± 5.2 2.5 ± 0.7 fpc Template Yes Yes
PD, Parkinson’s Disease; SD, standard deviation; UPDRS, Unified Parkinson’s disease rating scale; beta, [123I] β-carboxymethyoxy-3-beta-(4-iodophenyl) tropane; fpcit, [123 fluoropropyl-carbomethoxy-3β-4-iodophenyltropane;
IPT, 123I-N-(3-iodopropen-2-yl)-2-carbomethoxy-3β-(4-chlorophenyl) tropane; SPECT, single-photon emission computed tomography; CI, confidence interval; PDD, Parkin n’s disease dementia; DAT, dopamine transporter;
UKPDS, United Kingdom Parkinson’s Disease society.
*Full range instead of standard deviation.
¥Disease duration calculated from diagnosis.
ǂDisease duration calculated from first symptoms.






















Suwijn et al. EJNMMI Research  (2015) 5:12 Page 5 of 8Seventeen articles were selected for further review. Of
these, five were excluded because the study population
overlapped with more complete or more recent publica-
tions. We contacted the authors of five additional studies
that had missing data [41-44]. One author responded
[23]. The other four articles were excluded. In the end,
eight studies fulfilled our selection criteria.Study characteristics
The characteristics of the included studies are shown in
Table 1. The eight included studies involved a total of
235 patients. There was only one study that assessed
patients with clinically uncertain parkinsonism [45], all
other studies included patients with a clinical diagnosis
of PD (five studies) or pathologically proven PD (two
studies). The mean disease duration at first SPECT im-
aging ranged from 2.4 to 7.9 years.
Two studies used pathological evaluation as the refer-
ence standard [46,47]. The other six studies used a sec-
ond DAT SPECT scan, at least 2 years later, as surrogate
reference standard [20,22,23,45,48,49]. The studies using
pathological evaluation were retrospective studies. All
but one of the studies that used a second DAT SPECT
scan was prospective studies.Risk of bias
The risk of bias in the included studies is shown in
Table 2. Most studies had at least one design flaw. Five
out of the eight studies had an unclear or a high risk of
bias regarding patient selection due to a poor descrip-
tion of patient recruitment. In three out of eight studies,
there was a concern regarding patient flow. There was a
selection of patients that received the reference standard
(second DAT SPECT or pathological evaluation). In two
studies, we found previous reports with more patients
than the ones selected. However, the reasons for exclu-
sion of the extra patients were not mentioned in theTable 2 Risk of bias as assessed with the Quadas-2 tool







Chouker, [20] + ? ?
Marek, [22] ? + +
Pirker, [23] + + +
Marshall, [49] + + +
Isaias, [48] ? ? ?
Perju-Dumbrava, [46] − ? ?
Colloby, [47] − ? ?
Eggers, [50] − + +
+Low risk, −High risk, ?Unclear Risk.manuscript. In four of the eight studies, it was unclear if
the assessor of the index test was blinded for the results
of the reference test and/or clinical diagnosis.Diagnostic accuracy
Only in the study of patients with clinically uncertain
parkinsonism, a high diagnostic accuracy of DAT SPECT
imaging was observed with sensitivity and specificity
rates of 98%. Only in two out of 99 patients, DAT
SPECT results at follow-up differed compared to the
initial DAT SPECT scan [49]. In the other seven studies -
that included patients with a clinical or neuropathological
diagnosis of PD - DAT SPECT imaging had sensitivity
rates of 100%. In six of these seven studies, specificity rates
could not be calculated as the reference tests indicated all
patients had nigrostriatal cell loss. In the study of Marek
and colleagues, 30 patients showed nigrostriatal cell loss
at imaging and two did not. Sensitivity and specificity rates
were both 100%. An important finding of all seven studies
is that the results did not change in the course of 2.0 to
3.7 years.Discussion
Our study indicates that DAT SPECT imaging may be
accurate in detecting the loss of nigrostriatal dopaminergic
cells. As anticipated, there are only two studies having
both DAT SPECT imaging and pathological evaluation.
None of these studies performed DAT SPECT imaging in
early-stage clinical PD or in patients with clinically uncer-
tain parkinsonism. However, these two studies show that
DAT SPECT imaging at medium-long disease duration
(4.1 to 7.9 years) is able to detect nigrostriatal cell loss
[46,47].
A limitation of this review is that the majority of in-
cluded studies performed serial DAT SPECT imaging in
patients with a high suspicion of PD. These studies were
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In the other studies, all included patients had a positive
reference standard and consequently specificity rates of
the index test could not be calculated. However, these
results are inline with the only study that evaluated the
diagnostic accuracy in patients with clinically uncertain
parkinsonism (sensitivity and specificity 98%).
Another limitation is that in four studies it is not clear
whether the investigators assessing the SPECT images
were blinded for signs and symptoms or for the refer-
ence standard.
Other (systematic) reviews on the accuracy of DAT
SPECT imaging showed somewhat lower sensitivity
(79 to 100%) and specificity (80 to 100%) [18,50,51].
These reviews used the clinical diagnosis at follow-up
as reference standard. The clinical diagnosis is accurate
in 65 to 94% of the patients compared to the final
pathological diagnosis [4,9-11]. The accuracy of the
clinical diagnosis increases with the duration of symp-
toms [49,52]. However, most studies and clinical trials
use the clinical diagnosis 3 to 36 months after the
initial diagnosis as reference standard [53-56]. This in-
accurate reference standard might explain that the ac-
curacy of DAT SPECT imaging is somewhat lower in
these studies.
Therefore, there is a need for an alternative in vivo
reference standard to detect nigrostriatal dopaminergic
cell loss in patients with parkinsonism. To evaluate
new screening methods, and ultimately the accuracy of
the clinical criteria for (early) PD, a reliable and prac-
tical reference standard to detect nigrostriatal cell loss
is needed [57-60]. The current reference standard
(gold standard), pathological evaluation, is accurate,
however, not very practical to use to evaluate the ac-
curacy of the clinical criteria because the time between
the clinical diagnosis and pathological diagnosis is typ-
ically long.
For clinical trials, it will be better and more practical
to have an accurate in vivo reference standard to ensure
no patients with other diagnoses are included. If disease-
modifying therapies become available, it will also be de-
sirable to identify patients as early as possible, maybe
even in a premotor phase [61,62]. Especially considering
that using the clinical criteria, based on motor symp-
toms, more than 50% of the dopamine producing neu-
rons are lost [61,62].
Conclusions
It seems that DAT SPECT imaging could be used as an
in vivo reference standard to detect nigrostriatal cell loss
and evaluate new diagnostic (screening) methods. How-
ever, considering only one study included patients with
diagnostic uncertainty more diagnostic accuracy studies
are needed to confirm this finding.Additional file
Additional file 1: MEDLINE and EMBASE search strategies.
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